- Home
- AAMI vs OCS Comparison
AAMI vs OCS Comparison
Compare AAMI & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAMI
- OCS
- Stock Information
- Founded
- AAMI 1980
- OCS 2003
- Country
- AAMI United States
- OCS Switzerland
- Employees
- AAMI N/A
- OCS N/A
- Industry
- AAMI Investment Managers
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- AAMI Finance
- OCS Health Care
- Exchange
- AAMI Nasdaq
- OCS Nasdaq
- Market Cap
- AAMI 1.1B
- OCS 956.4M
- IPO Year
- AAMI N/A
- OCS N/A
- Fundamental
- Price
- AAMI $38.79
- OCS $17.87
- Analyst Decision
- AAMI Hold
- OCS Strong Buy
- Analyst Count
- AAMI 3
- OCS 3
- Target Price
- AAMI $30.33
- OCS $35.33
- AVG Volume (30 Days)
- AAMI 282.3K
- OCS 15.6K
- Earning Date
- AAMI 07-31-2025
- OCS 08-26-2025
- Dividend Yield
- AAMI 0.10%
- OCS N/A
- EPS Growth
- AAMI 46.05
- OCS N/A
- EPS
- AAMI 2.40
- OCS N/A
- Revenue
- AAMI $519,799,999.00
- OCS $847,333.00
- Revenue This Year
- AAMI $5.28
- OCS $10.23
- Revenue Next Year
- AAMI $6.24
- OCS $912.87
- P/E Ratio
- AAMI $16.18
- OCS N/A
- Revenue Growth
- AAMI 18.00
- OCS N/A
- 52 Week Low
- AAMI $21.49
- OCS $10.79
- 52 Week High
- AAMI $39.85
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- AAMI N/A
- OCS 34.15
- Support Level
- AAMI N/A
- OCS $17.99
- Resistance Level
- AAMI N/A
- OCS $18.90
- Average True Range (ATR)
- AAMI 0.00
- OCS 0.41
- MACD
- AAMI 0.00
- OCS -0.17
- Stochastic Oscillator
- AAMI 0.00
- OCS 7.44
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.